Outlook Therapeutics, Inc.OTLKNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 57% recommend buying.

Consensus Rating

Buy

14 analysts·Moderate coverage

57%

Rating Distribution

Strong Buy

00%

Buy

857%

Hold

643%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 127% higher.

Bear Case

$1.00

+127%

Consensus

$1.00

+127%

Bull Case

$1.00

+127%

Price Range14 analysts

Low

Consensus

High

$1.00

Current Target

Current Price

$0.44

Upside to Target

$0.56

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.77(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+129.89%

EPS—

FY2028

Rev-53.00%

EPS—

FY2029

Rev+30.00%

EPS—

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:-12.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 2, 2026Chardan Capital

Outlook Therapeutics price target lowered to $1 from $3 at Chardan

Target:$1.00

+51.5%from $0.66

Aug 29, 2025H.C. Wainwright

Outlook Therapeutics downgraded at H.C. Wainwright

Target:$1.00

-8.3%from $1.09

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance